Table 2

Six-month and 12-month outcomes in eyes with HRVO, compared with eyes with BRVO or CRVO

HRVOBRVOP value
(vs HRVO)
CRVOP value
(vs HRVO)
Eyes, n79590344
VA (letters)
 VA baseline, mean (SD)53.8 (17.7)59.4 (14.9)0.00951.9 (18.7)0.40
 VA 6 months, mean (SD)69.9 (13.7)69.8 (14)0.9660.7 (21.6)<0.001
 VA 12 months, mean (SD)70.2 (15.3)70.8 (14)0.7460.4 (23)<0.001
Change in VA (letters)
 ΔVA 6 months, mean (95% CI)16.1 (12.6 to 19.6)10.4 (9.3 to 11.5)0.0038.8 (6.6 to 11.1)<0.001
 ΔVA 12 months, mean (95% CI)16.4 (13.1 to 19.7)11.4 (10.2 to 12.6)0.0068.5 (6.1 to 10.9)<0.001
 Adjusted ΔVA 12 months, mean (95% CI)15.6 (11.9 to 19.3)13.2 (11.1 to 15.2)0.195.9 (3.6 to 8.3)<0.001
 Gained ≥15 letters, %49380.07400.17
 Lost ≥15 letters, %130.5013<0.001
 >70 letters, baseline/12 months, %24/6832/680.15/1.021/450.54/<0.001
 ≤35 letters, baseline/12 months, %20/39 /30.007/1.022/160.88/<0.001
Central subfield thickness (μm)
 CST baseline, mean (SD)550 (186)482 (159)0.004630 (223)0.002
 CST 6 months, mean (SD)332 (112)342 (115)0.45402 (213)<0.001
 CST 12 months, mean (SD)319 (124)330 (105)0.31371 (181)0.001
Change in CST (μm)
 Δ CST 6 months, mean (95% CI)−214 (−257 to –172)−141 (−154 to –127)0.003−229 (−258 to –200)0.60
 Δ CST 12 months, mean (95% CI)−231 (−277 to –184)−151 (−166 to –137)0.003−259 (−287 to –231)0.33
 Adjusted Δ CST 12 months, mean (95% CI)−218 (−253 to –183)−204 (−224 to –184)0.42−173 (−195 to –150)0.019
Treatment and visits
 Injections, median (Q1, Q3)*8 (6, 10)8 (5, 9)1.08 (5, 10)1.0
 Visits, median (Q1, Q3)*9 (9, 11)10 (8, 12)0.3811 (8, 13)0.12
 Suspension of treatment, n (%)†12 (15)96 (16)1.041 (12)0.45
 Never became inactive in 12 months, n (%)12 (15)174 (29)0.00785 (25)0.07
 VEGF switchers, n (%)11 (14)81 (14)1.0036 (10)0.43
 Steroid switchers, n (%)1 (1)38 (6)0.0720 (6)0.15
 Non-completion of 12 months, n (%)9 (11)100 (17)0.2658 (17)0.30
  • Significant differences between HRVO vs BRVO and HRVO vs CRVO are in bold (p<0.05).

  • Adjusted, using analysis of covariance controlling for first treatment age and baseline VA or CST as fixed effects and nesting within patients (both eyes) or the same practice as random effects.

  • *Calculated only in completers receiving VEGF monotherapy throughout with Generalised Poisson models used to generate p values.

  • †Periods >180 days containing recorded visits and no treatment.

  • BRVO, branch RVO; CRVO, central retinal vein occlusion; CST, central subfield thickness; HRVO, hemiretinal vein occlusion; VA, visual acuity; VEGF, vascular endothelial growth factor.